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Summary
Blood samples from 125 families with classic type 2
neurofibromatosis with bilateral vestibular schwanno-
mas were analyzed for mutations in theNF2 gene. Caus-
ative mutations were identified in 52 families. In five
families, the first affected individual in the family (the
index case) was a mosaic for a disease-causingmutation.
Only one of nine children from the three mosaic cases
with children are affected. Four of these nine children
inherited the allele associated with the disease-causing
mutation yet did not inherit the mutation. NF2 muta-
tions were identified in only 27/79 (34%) of sporadic
cases, compared with 25/46 (54%) of familial cases
( ). In 48 families in which a mutation has notP ! .05
been identified, the index cases have had 125 children,
of whom only 29 are affected with NF2 and of whom
only a further 21 cases would be predicted to be affected
by use of life curves. The 50/125 (40%) of cases is sig-
nificantly less than the 50% expected eventually to de-
velop NF2 ( ). Somatic mosaicism is likely to beP ! .05
a common cause of classic NF2 and may well account
for a low detection rate for mutations in sporadic cases.
Degrees of gonosomal mosaicism mean that recurrence
risks may well be !50% in the index case when a mu-
tation is not identified in lymphocyte DNA.
Introduction
Neurofibromatosis type 2 (NF2 [MIM 101000]) is an
autosomal dominant condition characterized by the de-
velopment of bilateral vestibular schwannomas (VS);
schwannomas of other cranial, spinal, and cutaneous
nerves; and cranial and spinal meningiomas (Kanter et
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al. 1980; Evans et al. 1992a; Parry et al. 1994). The
National Institutes of Health Consensus meeting in 1987
laid out firm diagnostic criteria for NF2 (National In-
stitutes Consensus Development Conference 1988).
These criteria meant that any individual with bilateral
VS was assumed to have the disease and that 50% of
offspring would be predicted to be affected. The NF2
gene was isolated in 1993, and, since that time, there
have been a number of reports of germ-line mutations
in large series of affected cases (Me´rel et al. 1995; Parry
et al. 1996; Ruttledge et al. 1996). Detection rates for
SSCP or denaturing gradient-gel electrophoresis have, in
general, been disappointingly low, even in classically af-
fected individuals. We previously reported an affected
individual with bilateral VS with somatic mosaicism for
a mutation (Bourn et al. 1994). Mosaicism refers to the
presence of a mutation, deletion, or chromosomal ab-
normality in a subpopulation of cells. This may be so-
matic, affecting somatic cells only; gonadal, affecting the
germ cells only; or gonosomal, affecting a proportion of
both types of cells. Since our original description, we
have detected four additional somatic-mosaic individu-
als (in three of whom the status at the germ-cell level is
unknown), including one gonosomal mosaic (Biljsma et
al. 1997). We report here three additional mosaic cases
and provide data suggesting that low-level mosaicism
may be common.
Patients and Methods
Individuals with classic NF2 (bilateral VS) have been
identified since 1989. Blood samples have been obtained
from 125 unrelated affected individuals, along with clin-
ical data and family history. Age and current status of
all children of index cases (i.e., the first affected indi-
vidual in each family) has been recorded. In addition,
samples from 16 individuals fulfilling the modified cri-
teria for diagnosis of NF2, which are listed in the Ap-
pendix (Evans et al. 1992b), and from 87 individuals
thought to be at risk of NF2 but not fulfilling these
criteria were analyzed, as described below.
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DNA Extraction from Peripheral Blood and Tumor
Samples
Genomic DNA samples were prepared from periph-
eral blood samples, on an Applied Biosystems 380A
DNA extractor, according to the manufacturer’s instruc-
tions. Tumor specimens from three cases fulfilling the
modified criteria were collected !1 h after surgery. The
tissue was snap frozen in liquid nitrogen and was stored
prior to extraction at 70C. The tissue was finely dis-
sected by means of a sterile scalpel and then was trans-
ferred into a 50-ml tube containing 40 ml of 2 # lysis
buffer and was agitated for 10 min. After lysis, the sus-
pension was centrifuged at 3,000 g for 10 min at 4C.
The supernatant was discarded, and the pellet was lysed
and centrifuged once more. DNA was then extracted
from the cell pellet, by means of an Applied Biosystems
380A DNA extractor.
Mutation Analysis
Genomic and tumor DNA samples were amplified
with primers for all 17 exons of theNF2 gene, by means
of primers described elsewhere (Me´rel et al. 1995). PCR
reactions were performed in 10-ml volumes containing
25 ng of prepared DNA, 5 pmol of each primer, 750
mmol of each dNTP/liter, and 0.3 U of Taq polymerase
(GibcoBRL), in 1# PCR buffer comprising 67mMTris-
HCl (pH 8.3), 16.6 mM ammonium sulfate, 3.7 mM
MgCl2, and 0.085 mg of BSA/ml. PCR amplificationwas
performed by a Techne PHC-2 thermal cycler, with the
following parameters: initial denaturation at 94C for 3
min; 30 cycles at 94C for 1 min, 60C (55C for exons
4 and 15 and 65C for exons 8, 10, and 16) for 1 min,
and 72C for 1 min; and a final extension at 72C for
10 min. SSCP/heteroduplex analysis was performed ac-
cording to the method described by Biljsma et al. (1997).
Mosaic Analysis
Mutant alleles were enriched for sequencing by ex-
cising the heteroduplex bands from heavily overloaded,
ethidium bromide–stained, SSCP/heteroduplex gels un-
der UV illumination. DNA was then eluted from the gel
slice by crushing and soaking overnight in 40ml of Tris-
EDTA buffer. The samples were then reamplified from
a 1/10 dilution of the eluate, by use of the specific exon
amplimers as described above, but the number of PCR
cycles was limited to 25. The PCR-amplified heterodu-
plex DNA was then sequenced by means of AmpliTaq
FS cycle sequencing kits (Perkin-Elmer), according to the
manufacturer’s protocol.
Quantitating the Degree of Mosaicism
Samples were PCR amplified in a 20-ml volume with
the relevant NF2 exon primers as described above. Four
microliters of PCR product was combined with loading
buffer and then electrophoresed on a 2% agarose gel
and was blotted onto Hybond N (Amersham), ac-
cording to the manufacturer’s instructions. Four repli-
cate amplifications of each test sample and of controls
were prepared, each set of amplifications being probed
sequentially with the relevant normal and mutant se-
quence-specific oligonucleotide (SSO). The sequences of
the SSOs were as follows: 896DTATG, 5′-cca gct atg tat
cgg-3′ (normal) and 5′-tcc agc tat cgg gaa-3′ (mutant);
and 1632DAG, 5′-caa gac aga aat cga-3′ (normal) and
5′-tca aga caa atc gag-3′ (mutant). Twenty nanograms
of each SSO was 5′-end labeled in a 10-ml volume for
30 min, with 20mCi of g[32]P-dATP and 10 U of T4
polynucleotide kinase (Amersham), in the manufac-
turer’s reaction buffer. The filters were prehybridized in
5 # saline sodium phosphate EDTA, 5 # Denhardt’s
solution, and 0.5% SDS, at 37C for 30 min, before
being probed. The filters were then hybridized for 1 h
in 5 ml of 5 # saline sodium phosphate (SSPE), 5 #
Denhardt’s solution, and 0.5% SDS, at 42C, before
being washed three times in 2 # SSPE and 0.5% SDS,
at 42C. The amount of hybridized radiolabeled SSO for
each sample was quantitated by imaging on an electronic
autoradiograph (Instant Imager; Packard) for 1 h. Each
filter was then stripped by being heated at 65C in 2#
SSPE and 0.5% SDS, for 1 h prior to being reprobed.
Proportion of Children Affected
All children born to the index case in each category
(mutation positive and mutation negative) were assessed
to determine their affected status. Unaffected individuals
in mutation-negative families (and in mutation-positive
families in which predictive testing had not taken place)
were assigned a residual risk of NF2 by use of cumulative
age-at-onset-of-symptoms curves derived from classi-
cally affected individuals (Evans et al. 1992b); for in-
stance, since 50% of NF2 cases present symptomatically
at age X21 years, the residual risk that an asymptomatic
individual of age 21 years would carry the mutated gene
would be 33%, by Bayes’s calculations. Allowance was
not made for further risk reduction that might derive
from negative neuroimaging. The predicted number of
affected children thus was calculated for mutation-pos-
itive and mutation-negative index cases.
Results
Classic NF2
A total of 52 causative mutations have been identified
in the 125 classically affected individuals (a frequency
of 40%); these mutations consist of 23 nonsense mu-
tations, 10 small frameshift deletions, 1 in-frame dele-
tion, 3 frameshift insertions, 5 missense mutations, 5
Table 1
Ages of Offspring, of Index Cases, Who Are at an Original Apparent 50% Risk of NF2 and Have Not
Undergone Genetic Testing
FAMILY (SEX OF INDEX CASE)
NO. OF OFFSPRING
Total Affected
Negative
by Genetic
Testing Unknown Status (Age[s] in Years)
Mutation positive:
16 (F) 7 2 3 2 (63a, 1a)
31 (M) 4 1 2 1 (32)
47 (M) 5 0 4 1 (30)
48 (M) 2 1 0 1 (20)
76 (M) 1 0 0 1 (10)
84 (M) 2 0 0 2 (6, 5)
100 (M) 3 1 0 2 (14, 9)
146 (F) 4 2 0 2 (31, 28)
Subtotal 28 7 9 12
Other families 48 31 17 0
Total 76 38 26 12
Mutation negative:
1 (M) 12 2 0 11 (73, 71, 67, 62, 60, 59, 52, 43, 38a, 28a)
4 (F) 1 0 0 1 (8)
12 (F) 2 1 0 1 (28)
19 (F) 1 0 0 1 (4)
23 (M) 2 0 0 2 (6, 3)
30 (F) 2 0 0 2 (17, 15)
41 (M) 2 1 0 1 (20)
42 (M) 2 0 0 2 (7, 4)
44 (F) 2 0 0 2 (22, 20)
45 (M) 3 0 0 3 (26, 23, 16)
50 (M) 1 0 0 1 (26)
55 (M) 6 2 0 4 (75, 70, 60, 34a)
60 (F) 1 0 0 1 (5)
65 (M) 2 0 0 2 (16, 13)
67 (M) 3 0 0 3 (10, 8, 5)
68 (M) 1 0 0 1 (9)
71 (F) 2 1 0 1 (14)
72 (M) 2 0 0 2 (6, 2)
80 (F) 1 0 0 1 (14)
83 (M) 3 0 0 3 (6, 4, 3)
85 (F) 1 0 0 1 (16)
89 (M) 2 0 0 2 (24, 22)
90 (M) 3 0 0 3 (10, 8, 5)
92 (M) 2 0 0 2 (25, 23)
94 (F) 3 0 0 3 (25, 23, 12)
112 (F) 5 2 2 1 (15)
113 (F) 3 0 0 2 (8, 6, 3)
117 (F) 1 0 0 1 (1)
131 (M) 1 0 0 1 (10)
136 (M) 1 0 0 1 (5)
148 (F) 2 0 0 2 (30, 28)
149 (F) 2 1 0 1 (33)
151 (F) 2 0 0 2 (42, 40)
152 (F) 3 0 0 2 (10, 6, 5)
172 (F) 3 0 0 3 (7, 7, 4)
173 (F) 2 0 0 2 (27, 25)
Subtotal 87 10 2 75
Other families 32 19 19 0
Total 125 29 21 75
NOTE.—Only families with individuals of unknown status are presented. Neither families that have no offspring
at risk for NF2, nor families in which genetic testing is complete are presented.
a Age at death.
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Table 2
Clinical Characteristics and Proportion of Cells Affected in Individuals Mosaic for NF2 Mutations
CASE
(GENDER) MUTATION(S)
CELLS
AFFECTED
(%)
AGE AT
(YEARS)
TUMORS
NO. OF
AFFECTED
CHILDRENOnset Diagnosis
1 (M) C169rT, Arg196rstop 10 41 49 Bilateral VS, 2 cranial schwannomas 0/5
2 (F) C784rT, Arg262rStop 37 23 43 Bilateral VS, 110 spinal schwannomas,
meningiomas
1/2
3 (M) 896DTATG 21 21 23 Bilateral VS, 1 spinal schwannoma 0/0
4 (F) 1632DAG 44 28 34 Bilateral VS only 0/2
5 (M) C784rT, Arg262rStop !10 48 50 Left-sided VS, 12 cutaneous schwannomas 0/2
splice-site mutations, and 5 large deletions (Evans et al.
1998). In 20 families, index cases were unavailable for
analysis. In the 46 families that have had an affected
second generation, 25 mutations (a frequency of 54%)
have been identified. Of the 79 sporadically affected in-
dividuals, mutations have been identified in only 27
(34%). This difference reaches statistical significance
( , df 1; ). Average age at onset of symp-2x  4.16 P ! .05
toms for the 36 truncating (nonsense/frameshift) mu-
tations present in full form was 18 years, with 21.7 years
being the average age at diagnosis.
Proportion of Affected Children
Index cases in the 52 mutation-positive families have
had a total of 76 children; 36 of these children have
developed NF2, and 2 have tested as mutation positive.
On the basis of DNA predictive testing, completely un-
affected status has been assigned to 26/38 unaffected
individuals. Of the 12 unaffected individuals not tested
in this way, 35% would be expected, on the basis of
age-at-onset curves, to develop the disease; thus, 3 or 4
additional children would be predicted to be affected in
the future. Therefore, 42/76 (55%) of offspring of mu-
tation-positive index cases either have or would be pre-
dicted to develop NF2.
The 73 mutation-negative index cases have had a total
of 125 children; 29 of these children have developed
NF2, and, on the basis of linkage testing, completely
unaffected status has been assigned to 21. Of the re-
maining cases, 21/75 (28%) would be predicted, on the
basis of age-related risks, to develop NF2 (Evans et al.
1992b). Thus, 50/125 (40%) of offspring of mutation-
negative index cases have or would be predicted to de-
velop NF2. The difference in predicted proportions of
affected and unaffected children was statistically signif-
icant, for both actual and predicted numbers (for actual
numbers, , df 1, ; for predicted num-2x  14.09 P ! .01
bers, , df 1, ). The ages of unaffected2x  3.842 P ! .05
individuals who are at an apparent 50% risk of NF2
and who have either mutation-positive or mutation-neg-
ative affected index parents are presented in table 1.
Mosaic Cases
Four of 125 index cases with classic NF2 were iden-
tified as somatic mosaics, and a fifth case was identified
from among the 16 cases fulfilling modified criteria.
These patients are summarized in table 2, along with
clinical data. Cases 1 and 2 have been published pre-
viously (Bourn et al. 1994; Biljsma et al. 1997). How-
ever, cases 3–5 are being described here for the first time
(case 5 is detailed in the following section, “Cases Ful-
filling Modified NF2 Criteria”). Cases 3 and 4 were no-
ticed because of their weak mutant bands on SSCP/
heteroduplex analysis (figs. 1A and B). In these two pa-
tients, the degree of mosaicism in peripheral lymphocytes
was calculated by comparison of the relative hybridi-
zation of SSOs in the mosaic PCR product and in normal
and heteroduplex controls (table 3 and fig. 2), by means
of an electronic-autoradiograph imager; a sample cal-
culation is given in a footnote to table 3. The mean
values from the four replicates are given alongside the
clinical characteristics in table 2.
Children from three of the mosaic cases were available
for analysis. Only 1/9 children inherited the disease-
causing mutation, but 4 additional children would be
expected, on the basis of analysis with intragenic and
flanking markers, to inherit the family mutation. In case
1, two children had inherited one chromosome 22 hap-
lotype and three children had inherited the other hap-
lotype from their sporadically affected father (D. Bourn,
personal communication). In case 2, an unaffected
brother inherited the same chromosome 22 as was in-
herited by his affected sister (Biljsma et al. 1997). In case
4, the affected father is informative for the markers
NF2CA3 (Bourn and Strachan 1995) and D22S280
(Weissenbach et al. 1992); NF2CA3 is located in the 5′
centromeric region of the NF2 gene, whereas D22S280
is located telomeric of NF2, showing, at a maximum,
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Figure 1 SSCP/heteroduplex analysis of mosaic cases 3 and 4. SSCP  single-strand conformation polymorphism (single-stranded DNA),
HD  heteroduplex and homoduplex (double-stranded DNA), N  normal control DNA, and MUT  reamplified heteroduplex from the
mosaic cases (to demonstrate how the mutation would appear in 100% of cells). A, NF2 exon 10. Lane 2, Case 3, the affected individual
mosaic for 896DTATG. Lanes 1 and 4, Unaffected parents of case 3. Lane 3, Unaffected brother of case 3. Note how weak the heteroduplex
bands are in lane 3 and how the SSCP shift is barely perceptible, compared with that in the MUT control lane. B, NF2 exon 15. Lane 2, Case
4, the individual mosaic for 1632DAG. Lanes 3 and 4, Unaffected children of case 4 (both of whom inherit opposite flanking haplotypes; see
fig. 3). Lane 5, Unaffected spouse of case 4. Note the weak heteroduplex bands and the weak but clearly visible SSCP band in the affected
individual. Contrast this with the results for case 3, in whom the level of mosaicism for the mutation is lower.
2-cM recombination with the gene. These markers thus
flank the location of the mutation, 1632DAG, which is
located in exon 15 at the 3′ end of the NF2 gene. Mu-
tation analysis of the two children showed that neither
of them was a carriers of 1632DAG (data not shown).
However, analysis with NF2CA3 and D22S280 showed
that these two children had inherited opposite flanking
haplotypes from their affected father (fig. 3).
Cases Fulfilling Modified NF2 Criteria
Sixteen patients fulfilling the modified NIH criteria
(Evans et al. 1992b) have been identified. Six causative
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Table 3
Estimating of the Degree of Somatic Mosaicism in Lymphocyte DNA in Cases 3 and 4
SAMPLE
GROSS COUNTS INa
(COUNTS/MIN)
R1 R2 R3 R4 R1 R2 R3 R4
Normal SSO Mutant SSO
NF2 PCR Product Probed with 896DTATG
Case 3 3,327 263 294 3,693 89 126 145 108
Controls:
896DTATG heteroduplex 3,035 203 141 2,679 564 1,179 1,078 331
Normal 4,303 418 267 2,481 4 17 18 6
NF2 Exon 15 PCR Product Probed with 1632DAG
Case 4 317 319 253 581 247 388 156 213
Controls:
1632DAG heteroduplex 552 195 262 628 663 1,287 759 794
Normal 457 169 312 280 12 26 14 20
PROCESSED DATA FOR ESTIMATION OF DEGREE OF
MOSAICISM FOR SAMPLE 896DTATG R1b
Gross Counts
[Normalized Signal]
No. of Signals
Cells
(counts/min)
Total
Equalized
Normal Mutant Normalized Normal Mutant (%)
Case 3 3,327 89 [478.93] 3,805.93 5,306.16 763.84 24.4
Controls:
896DTATG heteroduplex 3,035 564 [3,035.00] 6,070.00 3,035.00 3,035.00 100
Normal 4,303 4 [21.52] 4,324.52 6,039.79 30.21 0
a Values are raw data, as measured on an electronic autoradiograph, from SSO probings of four replicate amplifications of DNA
extracted from peripheral lymphocytes from the case, a reamplified heteroduplex control, and a normal (mutation-negative) control.
R1–R4  four replicates probed.
b For each replicate pair of probings, the data for the mutant SSO were normalized to compensate for the differing hybridization
frequencies of the normal and mutant probings. The heteroduplex control was used to derive a normalization factor for the mutant
data, by taking the heteroduplex-normal cpm:heteroduplex mutant cpm ratio for each replicate. Thus, for 896DTATG R1, the
normalization factor is 3,035/564. A total normalized signal (TNS) value then was calculated, by a summing of the normal and
normalized-mutant signals. To compensate for the varying amplification efficiencies of the samples, the TNS for each sample was
then equalized to that of the heteroduplex control. The equalization factor for each sample was calculated by taking the heteroduplex-
control TNS:sample TNS ratio. Thus, for case 3, the equalization factor is 6,070/3,805.93, and that for the normal control is
6,070/4,324.52. An equalized signal (ES) for each hybridization was then calculated by multiplication of the normalized signals
by the sample specific equalization factor. Finally, the estimation of the percentage of cells carrying the mutation was calculated,
by means of the following formula, which compensates for the cross-hybridization of the mutant probe to the normal sequence:
% of cells  {[test sample (mutant ES)  normal control (mutant ES)]/[heteroduplex control (mutant ES) normal control (mutant
ES)]} # 100, which, for case 3, is [(763.84  30.21)]/[(3,035  30.21)] # 100, or 24.4.
mutations (a frequency of 37.5%) have been identi-
fied—2 nonsense mutations, 2 frameshift deletions, 1
frameshift insertion, and 1 splice-site mutation. Of 12
cases with unilateral VS plus two other NF2 features, 4
had mutations, whereas 2/4 (50%) of cases withmultiple
meningiomas plus two other NF2 features were muta-
tion positive. No mutations were found in samples from
87 other patients with features suggestive of NF2. These
features varied, from unilateral VS at a young age to
patients with meningiomatosis or schwannomatosis,
with some individuals nearly fulfilling the modified cri-
teria. VS tumors have been analyzed in three patients
from the modified-criteria group in whom a mutation
was not identified in blood DNA. Both mutational hits
in the NF2 gene were established in two of the cases; in
one of these, case 5, a second tumor (subcutaneous
schwannoma) in the same individual has shown, in exon
8, an identical mutation, which was not found by further
analysis of blood (fig. 4). It is of note that this indi-
vidual’s tumors are predominantly left sided, with only
two subcutaneous nerve-related tumors (presumably
schwannomas) on the right.
Discussion
This study has shown that a higher proportion of mu-
tations are found in NF2 families in which vertical trans-
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Figure 3 Pedigree, haplotypes, and mutation-screening results
for case 4. The phase of inheritance of 1632DAG in I:1 is not known
(which is indicated by the question mark [?]). II:1 and II:2 inherit
opposite flanking haplotypes from I:1, but neither sibling inherits
1632DAG.
Figure 2 SSO analysis of the mosaic cases, 3 and 4. The normal and mutant probings originate from the same filter, which was sequentially
probed, stripped, and reprobed. A, NF2 exon 10, mutation 896DTATG, case 3. Lanes 1 and 4, Affected case 3. Lanes 2 and 5, Normal control.
Lanes 3 and 6, Heteroduplexes from case 3, reamplified. Lane 7, No-DNA control. B, NF2 exon 15, mutation 1632DAG, case 4. Lanes 1 and
4, Unaffected control. Lanes 2 and 5, Affected case 4. Lanes 3 and 6, Heteroduplexes from case 4, reamplified. Lane 7, No-DNA control.
mission of the disease is known to have taken place. It
also shows that the proportion of children predicted to
be affected in mutation-negative families is less than ex-
pected. We propose that these statistically significant dif-
ferences are due to somatic mosaicism in a relatively high
proportion of index cases. Somatic mosaicism has been
identified in 4/105 families in which the index case was
available for analysis. Low levels of mosaicism are less
likely to be detected by SSCP, and this consequently
could partly explain the low mutation-detection rate
(35%–45%) in many studies (e.g., Me´rel et al. 1995;
Kluwe et al. 1996; Ruttledge et al. 1996), including the
current study. A higher detection rate, 63%, reported in
a smaller study (MacCollin et al. 1994), could be due
to the relatively high number of familial cases. It is also
the most likely explanation for the lower-than-expected
number of affected offspring born to sporadic classically
affected individuals. When cumulative age-at-onset-of-
symptoms curves are used, the proportion of currently
unaffected children predicted to be affected is likely to
be exaggerated. This is because many of these children
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Figure 4 SSCP/heteroduplex analysis of NF2 exon 8 in mosaic
case 5, who fulfilled modified NF2 criteria. Lane L, PCR amplifications
of DNA from peripheral lymphocytes of case 5. Lane T1, PCR am-
plifications of DNA from VS of case 5. Lane T2, PCR amplifications
of DNA from subcutaneous schwannoma of case 5. Lane N, DNA
from a normal control sample. An SSCP shift corresponding to the
C784rT mutation is clearly visible in T1 and T2. T1 and T2 appear
different because the second mutation in tumor T1 is a point mutation
in the splice-donor site of intron 14, whereas the second mutation in
tumor T2 is a deletion encompassing NF2 exon 8, making this sample
hemizygous for C784rT. Abbreviations are as in figure 1.
had craniospinal imaging and detailed clinical exami-
nation, which would identify mutation carriers many
years before the onset of symptoms. Thus, the true pro-
portion of affected individuals born to mutation-nega-
tive cases may be even lower. Furthermore, nine children
of the four mosaic cases also were included in the anal-
ysis of mutation-positive families. Since only one of these
children was affected, exclusion of these families would
have made the final results even more significant. Both
the 20% fewer children born to index cases in mutation-
negative families and the similar difference, in detection
rates, between sporadic and familial cases means that as
many as 15% of index cases in families could be mosaic
cases.
Although there has been a great deal of speculation
about the importance of germinal mosaicism, little has
been attributed to the effects of low-level somatic mo-
saicism in the affected individual. Many conditions in
which germinal mosaicism appears to be significant
would not be expected to be expressed clinically if they
were to exist in somatic mosaic form. However, ex-
pression of Duchenne muscular dystrophy (DMD) in a
male mosaic for a DMD-gene deletion recently has been
described elsewhere (Saito et al. 1995). It also has been
shown that mothers who transmit DMD deletions can
have high-level somatic mosaicism also (Bunyan et al.
1995). Although many conditions would not be ex-
pressed if sufficient cells were homozygous normal, tu-
mor-prone conditions may well manifest with only a
small proportion of affected cells. Individuals with NF2
often develop hundreds of tumors, with VS being of early
onset, bilateral, and, often, multifocal (Evans et al.
1992a). Mosaicism confined to the neural crest in a high
enough proportion of cells is likely to present with classic
NF2. Such mosaicism has been recently described for
multiple endocrine neoplasia type 2 (MEN2): a RET
mutation was found in the normal thyroid and in a med-
ullary carcinoma from the same patient but was not
found in the blood (Komminoth et al. 1995). The pres-
ence of such mosaicism in conditions with a high new-
mutation rate had been predicted (Hall 1988). The pres-
ence of mosaicism in cytogenetically detectable abnor-
malities is more readily screened for and therefore has
been reported more frequently (Sampson et al. 1997).
Transmission of other tumor-prone genes frommosaic
cases has been described for p53 (Kovar et al. 1992)
and, more recently, for retinoblastoma (Thonney et al.
1996) In NF1, mosaicism may appear in a segmental
form (Huson 1994; Moss and Green 1994). Although
risks of transmission to offspring of segmental cases are
thought to be low, classically affected children occa-
sionally have been described (Huson 1994; Moss and
Green 1994). However, there has been little speculation
as to the contribution of somatic mosaicism to classic
disease in tumor-prone conditions. It is plausible that
many conditions—including von Hippel–Lindau dis-
ease, MEN2, NF1, familial adenomatous polyposis, reti-
noblastoma, and many other of these conditions with a
relatively high spontaneous-mutation rate—can be
caused by somatic mosaicism. Indeed, the incomplete
detection of mutations for many of these conditions also
could be explained partly by this phenomenon.
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The five mosaic cases described here are relatively
mildly affected. All the cases have truncating mutations,
which would normally be associated with more severe
disease (Parry et al. 1996; Ruttledge et al. 1996; Evans
et al. 1998). The average age at onset of symptoms in
these five cases was 32 years, compared with 12 years
in one recent series (Parry et al. 1996) and 18 years in
the remaining truncating mutations reported here. Al-
though these numbers are small, it could be speculated
that somatic mosaic cases will have milder disease but
that their offspring would bemore severely affected.This
could explain, in part, intergenerational variation,which
could mimic anticipation. It is perhaps unlikely that mu-
tations associated with a more benign phenotype, such
as many splice-site and missense mutations (Parry et al.
1996; Ruttledge et al. 1996; Evans et al. 1998), would
manifest in the mosaic state.
A similar proportion of sporadic patients fulfilling
modified NF2 criteria compared to sporadic classic dis-
ease were found to have mutations. Although the num-
bers are small, this would suggest that modified criteria
are not overinclusive. The presence of a unilateral VS
would make schwannomatosis not caused by NF2 very
unlikely, and the presence of at least two NF2 manifes-
tations in patients with multiple meningiomas would
also discount overlap with meningiomatosis. However,
it is likely that these criteria will identify a number of
mosaic cases, such as the fifth case described here.
This report has highlighted the potential importance
of somatic mosaicism as a cause of NF2. As many as
15% of index cases could represent mosaicism that is
at a level insufficient to be detected in blood. Transmis-
sion risks may be lower in index cases in whom a mu-
tation is not identified. Detection of low-level mosaicism
may be possible in analysis of tumors from multiple
samples from the same individual (an identical mutation
in two or more tumors would be virtually conclusive).
If a recurrent mutation is identified, it could be used for
presymptomatic testing of the next generation.
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Appendix
Diagnostic Criteria for NF2
Primary Criteria
Bilateral VS or family history of NF2 plus either (1)
unilateral VS or (2) any two of the following: menin-
gioma, glioma, neurofibroma, schwannoma, and pos-
terior subcapsular lenticular opacities
Additional Criteria
Unilateral VS plus any two of the following: menin-
gioma, glioma, neurofibroma, schwannoma, and pos-
terior subcapsular lenticular opacities
Multiple (two or more) meningiomas plus either (1)
unilateral VS or (2) any 2 of the following: glioma, neu-
rofibroma, schwannoma, and cataract
Electronic-Database Information
Online Mendelian Inheritance in Man (OMIM), http://
www.ncbi.nim.nih.gov/omim (for NF2 [MIM 101000])
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